Clinical Trials Browser

Active not recruiting × encorafenib × Clear all

NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT05195632 2026-05-01

OCEANII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05308446 2026-04-21

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Neoplasms

NCT07022457 2026-04-13

UK-EnBiRiM

Active not recruiting

Melanoma

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05217446 2026-04-07

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04074096 2026-03-25

BEPCOME-MB

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Skin Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colonic Neoplasms

NCT06578559 2026-01-05

BRICKET

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04526782 2025-11-18

ENCO-BRAF

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 2 FDA

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT03235245 2025-08-01

EBIN

Phase 2 Active not recruiting

Melanoma

NCT03839342 2025-02-03

BEAVER

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05270044 2023-11-22

COLUMBUS-AD

Phase 3 Active not recruiting

Melanoma